'I was 35 and didn't even know what MS was'
Kate Dawson, from Ponteland, Northumberland, is now 49 and wants more people to be aware of the symptoms so they can get help earlier.
The condition affects the brain and spinal code and can cause pain, mobility issues and fatigue.
More than 150,000 people live with it in the UK, yet a new survey from the MS Society shows only one in five UK adults know it is most likely to be diagnosed in people in their 30s and 40s.
The charity spoke to 2,000 people and also found only a third knew women were more likely to be diagnosed with MS than men, and that smoking and obesity increased a person's risk of developing it.
Ms Dawson, a fitness instructor at the time, said she became aware something was wrong when running became more difficult.
"I kept tripping over tree roots, my right leg would start dragging and I had to be aware of lifting it," she said
She later discovered an earlier medical episode may have been an early symptom.
"During my GSCEs, I lost the sight in one eye for a bit and I just thought it was stress, but they told my dad they couldn't diagnose it at that stage because you had to have multiple episodes.
"It was horrible when I finally found out, I was in denial, I didn't want to tell people, I didn't even tell my mum, I didn't want to burden anyone else."
Ms Dawson said her main symptoms now were fatigue, loss of balance and strength in her legs.
"But I do a lot of cold water swimming and that seems to really help," Ms Dawson added.
MS is the most common neurological condition among young adults and Sarah Rawlings from the MS said it could be "debilitating, exhausting and unpredictable".
She added: "However greater understanding can make a huge difference and make conversations with family, friends and employers that little bit easier."
Follow BBC North East on X, Facebook, Nextdoor and Instagram.
Scientists crack mystery of how MS gene spread
'My son's had more than 200 carers in five years'
Hopes for multiple sclerosis drugs trial
MS Society
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
a day ago
- Fox News
Specific symptoms could warn of MS more than a decade before diagnosis, study finds
People with multiple sclerosis (MS) may show warning signs long before classic symptoms appear — and mental health concerns could be among the first red flags, according to new research. A University of British Columbia (UBC) study, published last week in JAMA Network Open, examined the medical records of 2,038 patients with the autoimmune disease and compared them to 10,182 patients without it. The researchers found that future MS patients had elevated rates of mental health-related issues, psychiatrist and general practice visits, and complaints of vague symptoms such as fatigue and pain — all as early as 15 years before the onset of clear symptoms. "These findings suggest that MS may begin much earlier than previously recognized, with mental health–related issues as early indicators," the researchers wrote. MS, which attacks the protective myelin coating around nerve cells in the brain and spinal cord, affects about one million adults in the U.S., according to Cleveland Clinic. While there is no known cause or cure, treatment can help manage symptoms and slow the progression of the disease, which can cause muscle weakness, vision changes, numbness and memory issues. Previous research has shown that in the five to 10 years leading up to an MS diagnosis, people typically seek medical attention more frequently for headaches, fatigue, sleep disorders, pain, gastrointestinal issues and psychiatric concerns, the researchers wrote. The UBC study, however, tracked physician visits in the 25 years leading up to the onset of symptoms in MS patients in British Columbia. They found a steady uptick in general practice visits starting 15 years out, followed by more frequent trips to psychiatrists beginning 12 years before symptoms. Neurology and ophthalmology visits increased eight to nine years prior, likely due to blurred vision or eye pain, two common early symptoms of MS. Three to five years before onset, emergency room and radiology visits rose sharply. Across nearly every specialty, physician visits peaked in the year before symptoms began. Psychiatrist consultations, in particular, skyrocketed 159% before MS onset, and mental health visits increased 76%, according to the research. The increase in psychiatric visits may correlate to the earliest stages of MS-related immune dysregulation, as higher levels of certain inflammation-related chemicals and problems with the blood-brain barrier can affect mood, the researchers noted. While most people who experience mental health issues, fatigue and headaches do not develop MS, the researchers said that recognizing and characterizing the "prodromal phase" — the early period marked by subtle symptoms — could speed up diagnosis and improve outcomes. "Mental health and psychiatric-related issues may be among the earliest features of the prodromal phase of MS, preceding nervous system-related symptoms and neurologist visits by several years," senior author Dr. Helen Tremlett, professor of neurology at UBC, told Fox News Digital. "This suggests that in the future, there may be an opportunity to recognize and manage MS early, maximizing mental health and brain reserve," she said. The findings also open "new avenues for research into early biomarkers, lifestyle factors and other potential triggers that may be at play during this previously overlooked phase of the disease," the researcher added. Monitoring for early warning signs could also potentially help to detect other brain diseases, like Alzheimer's or ALS, and ensure early intervention, Tremlett noted. For more Health articles, visit Between 2016 and 2021, MS cases increased globally from about 2.2 million to as many as 2.9 million, according to research published in July in the journal Frontiers in Neurology. The disease has gained public attention in recent years as celebrities like Selma Blair, Christina Applegate and Montel Williams have shared their experiences of living with MS.
Yahoo
2 days ago
- Yahoo
Skittles, M&M's more candy options free of synthetic dyes coming in 2026
Starting next year, Skittles, M&M's, Starburst and Extra Gum will be available free of artificial colors to consumers nationwide. Mars Wrigley North America announced last month that products across four categories of its popular treats -- gum, fruity confections and chocolate candy -- will be made "without Food, Drug & Cosmetic (FD&C) colors" starting in 2026. The first brands to be available without without FD&C colors will include M&M's Chocolate, Skittles Original, Extra Gum Spearmint and Starburst Original fruit chews, the company said. Kraft Heinz, General Mills to remove artificial dyes from food products over next 2 years News of the candy maker's move away from synthetic color additives was first announced on July 24, as reported by Bloomberg. "Mars Wrigley North America has been on an innovation journey over the past few years, dedicated to bringing products that provide consumers delicious choices when they treat," the company said in a press release. "In the United States, we are engaged closely with regulators and aware of the increased dialogue and activity regarding colors. All our products meet the high standards and applicable regulations set by food safety authorities around the world, including the FDA." Anton Vincent, president of Mars Wrigley North America, added that the company's approach "is always consumer-focused and science-led." Mars Wrigley said its experts "are exploring alternatives that satisfy scientific safety criteria, technical requirements and consumer preferences." Once the company has identified a "fully effective, scalable solution," it will share updates on timing and specific product commitments, it said. The move makes Mars Wrigley an early entrant to a growing list of major consumer product goods companies offering a choice of naturally colored products. The change comes amid a push from Health and Human Services Secretary Robert F. Kennedy Jr. to crack down on synthetic food additives as part of his initiative to "Make America Healthy Again." Among those efforts are proposals to phase out artificial food dyes in favor of natural alternatives. In June, Kraft Heinz and General Mills announced plans to remove artificial food dyes from some products within the next two years. Several other large food manufacturers -- including PepsiCo, ConAgra, The Hershey Company, McCormick & Co., J.M. Smucker, Nestlé USA and more -- have announced similar plans in recent months. As of May, the U.S. Food and Drug Administration has approved three additional color additives from natural sources that are in line with the Department of Health and Human Services' goals, which can be used in a wide range of products from gum to breakfast cereal. "For too long, our food system has relied on synthetic, petroleum-based dyes that offer no nutritional value and pose unnecessary health risks. We're removing these dyes and approving safe, natural alternatives -- to protect families and support healthier choices," Kennedy said in a statement at the time. Multiple states have also passed legislation to eliminate food dyes from school lunch programs. Solve the daily Crossword
Business Wire
3 days ago
- Business Wire
Sapient Publishes Breakthrough rLC-MS Metabolomics Study in Over 26,000 Samples, Revealing Metabolic Aging Clock and Disease Insights
SAN DIEGO--(BUSINESS WIRE)-- Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has published a pioneering study detailing the application of its rLC-MS system for non-targeted metabolomics analysis in more than 26,000 plasma samples, which led to the discovery of key metabolic phenotypes ('metabotypes') that correlate with common diseases and enabled development of a machine learning (ML)-based metabolic aging clock found to accurately predict accelerated aging in various chronic diseases, with dynamic reversal of aging following definitive therapy. The samples were analyzed by rLC-MS to capture over 15,000 metabolites and lipids per sample, providing the first deep view into the comprehensive landscape of human small molecule chemistry. For this study, a subset of samples from Sapient's DynamiQ™ biorepository — comprised of more than 62,000 total plasma samples — were selected from 6,935 individuals to represent diverse demographic backgrounds and disease profiles. The samples were analyzed by rLC-MS to capture over 15,000 metabolites and lipids per sample, providing the first deep view into the comprehensive landscape of human small molecule chemistry. These molecules are derived from both endogenous and exogenous sources and therefore reflect dynamic physiological processes and environmental influences, making them important biomarkers to understand and predict clinically relevant physiological states. Across individuals, biological variation was markedly higher than technical variation, indicating good power to discern biological effects. Using the large-scale dataset generated via rLC-MS, Sapient was able to identify several distinct subpopulations with metabotypes that correlate with heterogeneous disease phenotypes, including strong associations with cardiometabolic disorders. These findings suggest that plasma metabolomics can be used to metabolically define subgroups, predict disease states, and develop molecular diagnostic tools. The rLC-MS dataset was also used to train an ML model to predict biological age and capture individual differences in rate of aging, in particular exploring how chronic human diseases may shorten lifespan. This metabolic aging clock successfully predicted accelerated aging in chronic human disorders as well as reversal of aging in kidney disease patients following transplantation, demonstrating that metabolomics may better capture dynamic changes in aging than biomedical data or epigenetic markers alone. 'These findings demonstrate the discovery power of the rLC-MS platform to capture a broad and dynamic landscape of chemical variation in human plasma, across a large population,' said Jeramie Watrous, PhD, first author on the paper and Co-Founder and Head of Analytical R&D at Sapient. 'The robust, large-scale datasets that can be generated with rLC-MS will substantially increase the ability to identify robust small molecule biomarkers, elucidate novel disease mechanisms, and predict biomedically relevant physiological states.' 'To answer our ambitious questions about shared and unique features of human biology at scale, we had to reimagine the entire technology stack, from our rLC-MS to an AI-driven pipeline for automated feature detection, annotation, and quality control,' said Saumya Tiwari, PhD, co-first author and Co-Founder and Head of Computational R&D Operations at Sapient. 'We built AI-powered custom software and a library of over 13,000 chemical standards to transform raw signal into meaningful biology. The result is a dynamic, high-resolution portrait of human individuality shaped by both biology and environment.' 'We've shown that non-targeted metabolomics data can be very valuable to train predictive models of complex physiological states,' said Tao Long, PhD, MBA, Co-Founder and Head of Data Science at Sapient. 'With our ML-based analyses, we find circulating metabolites hold close association with key human health and disease phenotypes, and can predict and read out complex, dynamic biological processes including biological aging, disease onset, and therapeutic response.' The full paper, entitled 'Rapid Liquid Chromatography-Mass Spectrometry (rLC-MS) for Deep Metabolomics Analysis of Population Scale Studies', can be accessed here. About Sapient Sapient is a leader in multi-omics data generation and insight delivery, providing bespoke services for proteomics, metabolomics, and lipidomics that enable biopharma sponsors to go beyond the genome to accelerate precision drug development. Utilizing cutting-edge, high-throughput mass spectrometry and biocomputational frameworks, Sapient enables comprehensive biomarker-phenotype mapping across thousands of biosamples for discovery of robust protein, metabolite, and lipid biomarkers, drug targets, and clinical signatures of drug response. The company's DynamiQ™ Insights Engine — a longitudinal database of integrated multi-omics and real-world data collected from tens of thousands of samples — enables rapid drug target identification, biomarker discovery and validation, and translational and clinical insights across all stages of drug development. For more information, visit
